Ahmad Naim

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Srđan Verstovšek, Jason Gotlib, Ruben A. Mesa et al. · Journal of Hematology & Oncology · 2017 · 286 citations · Full text

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Alessandro M. Vannucchi, Srđan Verstovšek, Paola Guglielmelli et al. · Annals of Hematology · 2017 · 90 citations · Full text

Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy

Eduardo Huarte, Roddy S. O’Connor, Michael T. Peel et al. · Clinical Cancer Research · 2020 · 86 citations · Full text

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey

Ruben A. Mesa, Carole B. Miller, Maureen Thyne et al. · Cancer · 2016 · 85 citations · Full text

Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review

Shernan G. Holtan, Jingbo Yu, Hannah Choe et al. · Bone Marrow Transplantation · 2022 · 42 citations · Full text